Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0MHAHZ
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Coltuximab ravtansine
|
|||||
| Synonyms |
HuB4-DM4; SAR-3419; Anti-CD19 humanized monoclonal antibody conjugated to DM4; Anti-CD19-DM4 immunoconjugate; Maytansin-loaded anti-CD19 mAb; SAR3419
Click to Show/Hide
|
|||||
| Organization |
ImmunoGen, Inc.; Sanofi
|
|||||
| Drug Status |
Phase 2
|
|||||
| Indication |
In total 4 Indication(s)
Diffuse large B-cell lymphoma [ICD11:2A81]
Phase 2
Acute lymphoblastic leukemia [ICD11:2B33]
Terminated in phase 2
Lymphoma [ICD11:2A85-2A90]
Terminated in phase 1
Non Hodgkin lymphoma [ICD11:2B33]
Terminated in phase 1
|
|||||
| Drug-to-Antibody Ratio |
3.5
|
|||||
| Structure |
|
|||||
| Antibody Name |
Coltuximab
|
Antibody Info | ||||
| Antigen Name |
B-lymphocyte antigen CD19 (CD19)
|
Antigen Info | ||||
| Payload Name |
Mertansine DM4
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through nucleophilic lysines.
|
|||||
| Combination Type |
Ravtansine
|
|||||
| Puchem SID | ||||||
| Drugbank ID | ||||||
| DrugMap ID | ||||||
| TTD ID | ||||||
| ChEBI ID | ||||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.